Search

Your search keyword '"Bosly, Andre"' showing total 245 results
Start Over Author "Bosly, Andre"
245 results on '"Bosly, Andre"'

1. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Author

Camus, Vincent, Belot, Aurélien, Oberic, Lucie, Sibon, David, Ghesquières, Hervé, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry Jo, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, and Tilly, Hervé

Published
2022
Full Text
View/download PDF

3. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors

Author

Chiche, Johanna, Reverso-Meinietti, Julie, Mouchotte, Annabelle, Rubio-Patiño, Camila, Mhaidly, Rana, Villa, Elodie, Bossowski, Jozef P., Proics, Emma, Grima-Reyes, Manuel, Paquet, Agnès, Fragaki, Konstantina, Marchetti, Sandrine, Briere, Josette, Ambrosetti, Damien, Michiels, Jean-François, Molina, Thierry Jo, Copie-Bergman, Christiane, Lehmann-Che, Jacqueline, Peyrottes, Isabelle, Peyrade, Frederic, de Kerviler, Eric, Taillan, Bruno, Garnier, Georges, Verhoeyen, Els, Paquis-Flucklinger, Véronique, Shintu, Laetitia, Delwail, Vincent, Delpech-Debiais, Celine, Delarue, Richard, Bosly, André, Petrella, Tony, Brisou, Gabriel, Nadel, Bertrand, Barbry, Pascal, Mounier, Nicolas, Thieblemont, Catherine, and Ricci, Jean-Ehrland

Published
2019
Full Text
View/download PDF

4. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Bosly, André, Stilgenbauer, Stephan, Thieblemont, Catherine, Szymczyk, Michal, Bouabdallah, Reda, Kneba, Michael, Hallek, Michael, Salles, Gilles, Feugier, Pierre, Ribrag, Vincent, Birkmann, Josef, Forstpointner, Roswitha, Haioun, Corinne, Hänel, Mathias, Casasnovas, René Olivier, Finke, Jürgen, Peter, Norma, Bouabdallah, Kamal, Sebban, Catherine, Fischer, Thomas, Dührsen, Ulrich, Metzner, Bernd, Maschmeyer, Georg, Kanz, Lothar, Schmidt, Christian, Delarue, Richard, Brousse, Nicole, Klapper, Wolfram, Macintyre, Elizabeth, Delfau-Larue, Marie-Hélène, Pott, Christiane, Hiddemann, Wolfgang, Unterhalt, Michael, and Dreyling, Martin

Published
2016
Full Text
View/download PDF

5. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Author

Delarue, Richard, Tilly, Hervé, Mounier, Nicolas, Petrella, Tony, Salles, Gilles, Thieblemont, Catherine, Bologna, Serge, Ghesquières, Hervé, Hacini, Maya, Fruchart, Christophe, Ysebaert, Loïc, Fermé, Christophe, Casasnovas, Olivier, Van Hoof, Achiel, Thyss, Antoine, Delmer, Alain, Fitoussi, Olivier, Molina, Thierry Jo, Haioun, Corinne, and Bosly, André

Published
2013
Full Text
View/download PDF

6. Outcomes of elderly diffuse large B-cell lymphoma patients treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Author

Camus, Vincent, Belot, Aurelien, Obéric, Lucie, Sibon, David, Ghesquieres, Herve, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry, Bosly, Andre, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, Tilly, Herve, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Abstract

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-Line R-CHOP delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in diffuse large B-cell lymphoma patients aged 60-80 years with an age-adjusted IPI score greater than or equal to 1 (registered as NCT00144755). We implemented a prospective long-term follow-up (LTFU) program at the end of this trial. The primary endpoints were progression-free survival (PFS) and Overall survival (OS). Relapse patterns and PFS/OS after the first progression (PFS2/OS2) were secondary endpoints. LNH03-6B was registered with ClinicalTrial.gov number NCT00144755. In the LNH03-6B trial, 304 and 296 patients were assigned to receive 8 cycles of R-CHOP14 or R-CHOP21, respectively. LTFU data were investigated for 256/384 (67%) patients who were still alive at the primary analysis. With a median follow-up of 10.1 years, 213 patients progressed, and 140 patients died without progression. The ten-year PFS was 40.4% (95% CI: 35.9-44.9). Ten-year OS was based on 302 deaths and estimated at 50% (43-56). One hundred and five of the 213 patients (49%) progressed after second-line therapy, and 77 patients died without a second progression (36%). The 1-year PFS2 and 1-year OS2 were estimated at 37.9% [31.4-44.5] and 55.8% [48.8-62.2], respectively. Ten years after randomization, the outcomes of patients treated for DLBCL were similar according to PFS and OS between the RCHOP-14 and R-CHOP21 groups. Progression/relapse led to poor prognosis after second-line chemotherapy in the pre-CAR-T era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population.

Published
2022

7. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Author

Récher, Christian, Coiffier, Bertrand, Haioun, Corinne, Molina, Thierry Jo, Fermé, Christophe, Casasnovas, Olivier, Thiéblemont, Catherine, Bosly, André, Laurent, Guy, Morschhauser, Franck, Ghesquières, Hervé, Jardin, Fabrice, Bologna, Serge, Fruchart, Christophe, Corront, Bernadette, Gabarre, Jean, Bonnet, Christophe, Janvier, Maud, Canioni, Danielle, Jais, Jean-Philippe, Salles, Gilles, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

8. 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study

Author

Decaudin, Didier, Mounier, Nicolas, Tilly, Hervé, Ribrag, Vincent, Ghesquières, Hervé, Bouabdallah, Krimo, Morschhauser, Franck, Coiffier, Bertrand, Le Gouill, Steven, Bologna, Serge, Delarue, Richard, Huynh, Anne, Bosly, André, Brière, Josette, and Gisselbrecht, Christian

Published
2011
Full Text
View/download PDF

10. Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network

Author

Hermine, Olivier, primary, Jiang, Linmiao, additional, Walewski, Jan, additional, Bosly, Andre, additional, Szymczyk, Michal, additional, Thieblemont, Catherine, additional, Pott, Christiane, additional, Salles, Gilles, additional, Feugier, Pierre, additional, Hübel, Kai, additional, Burroni, Barbara, additional, Klapper, Wolfram, additional, Unterhalt, Michael, additional, Hoster, Eva, additional, and Dreyling, Martin, additional

Published
2021
Full Text
View/download PDF

12. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

Author

Reyes, Felix, Lepage, Eric, Ganem, Gerard, Molina, Thierry J., Brice, Pauline, Coiffer, Bertrand, Morel, Pierre, Tilly, Herve, Ferme, Christophe, Bosly, Andre, Laurent, Guy, and Lederlin, Pierre

Subjects
Chemotherapy -- Health aspects, Radiotherapy -- Health aspects, Lymphomas -- Care and treatment, Cancer -- Chemotherapy, Cancer -- Health aspects
Abstract

A randomized trial comparing chemoradiotherapy with chemotherapy is conducted to determine the optimal therapy for noneldery persons with low-risk localized lymphoma. The results obtained from the trial conclude that in patients less than 61 years of age, chemotherapy with three cycles of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) followed by sequential consolidation is superior to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radiotherapy for the treatment of low-risk localized lymphoma.

Published
2005

19. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma

Author

Solal-Celigny, Philippe, Lepage, Eric, Brousse, Nicole, Reyes, Felix, Haioun, Corinne, Leporrier, Michel, Peuchmaur, Michel, Bosly, Andre, Parlier, Yolaine, Brice, Pauline, Coiffier, Bertrand, and Gisselbrecht, Christian

Subjects
Non-Hodgkin's lymphomas, Interferon alpha -- Health aspects
Abstract

Interferon alfa combined with chemotherapy may enhance the therapy response rate in patients with advanced non-Hodgkin's lymphomas. Non-Hodgkin's lymphomas are malignant tumors of the lymph nodes. Interferon alpha is a component of the immune response with antiviral.Researchers assigned 119 patients to chemotherapy and 123 to chemotherapy plus interferon alpha. Eighty-two chemotherapy patients and 104 chemotherapy plus interferon alpha patients responded to therapy by the end of the trial. By that time, 39 patients in the chemotherapy group and 26 in the interferon alpha group had died. Patients treated with chemotherapy alone had average event-free survival rates of 19 months. Patients who also took interferon alpha averaged 34 months without incident. At three years, 89% of the interferon alpha patients survived compared to 69% of the chemotherapy patients. Interferon alpha therapy was stopped in 13 patients and decreased in 19 others due to adverse effects.

Published
1993

22. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Author

Briere , Jose, Cabeçadas , Jose, Salles , Gilles, Gaulard , Philippe, Bosly , Andre, Coiffier , Bertrand, Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), and CHU Dinant-Godinne UCL Namur

Subjects
hemic and lymphatic diseases, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract

International audience; Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Methods Patients with previously untreated DLBCL or other aggressive B-cell lymphoma were 60 to 80 years old, had CR or PR after six or eight cycles of R-CHOP, and were randomly assigned to lenalidomide maintenance 25 mg/d or placebo for 21 days of every 28-day cycle for 24 months. The primary end point was progression-free survival (PFS). Results A total of 650 patients were randomly assigned. At the time of the primary analysis (December 2015), with a median follow-up of 39 months from random assignment, median PFS was not reached for lenalidomide maintenance versus 58.9 months for placebo (hazard ratio, 0.708; 95% CI, 0.537 to 0.933; P = .01). The result was consistent among analyzed subgroups (eg, male v female, age-adjusted International Prognostic Index 0 or 1 v 2 or 3, age younger than 70 v ≥ 70 years), response (PR v CR) after R-CHOP, and positron emission tomography status at assignment (negative v positive). With longer median follow-up of 52 months (October 2016), overall survival was similar between arms (hazard ratio, 1.218; 95% CI, 0.861 to 1.721; P = .26). Most common grade 3 or 4 adverse events associated with lenalidomide versus placebo maintenance were neutropenia (56% v 22%) and cutaneous reactions (5% v 1%), respectively. Conclusion Lenalidomide maintenance for 24 months after obtaining a CR or PR to R-CHOP significantly prolonged PFS in elderly patients with DLBCL.

Published
2017

23. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Author

Thieblemont, Catherine, primary, Tilly, Hervé, additional, Gomes da Silva, Maria, additional, Casasnovas, Rene-Olivier, additional, Fruchart, Christophe, additional, Morschhauser, Franck, additional, Haioun, Corinne, additional, Lazarovici, Julien, additional, Grosicka, Anida, additional, Perrot, Aurore, additional, Trotman, Judith, additional, Sebban, Catherine, additional, Caballero, Dolores, additional, Greil, Richard, additional, van Eygen, Koen, additional, Cohen, Amos M., additional, Gonzalez, Hugo, additional, Bouabdallah, Reda, additional, Oberic, Lucie, additional, Corront, Bernadette, additional, Choufi, Bachra, additional, Lopez-Guillermo, Armando, additional, Catalano, John, additional, Van Hoof, Achiel, additional, Briere, Josette, additional, Cabeçadas, Jose, additional, Salles, Gilles, additional, Gaulard, Philippe, additional, Bosly, Andre, additional, and Coiffier, Bertrand, additional

Published
2017
Full Text
View/download PDF

24. Unmet needs in the scientific approach to older patients with lymphoma

Author

Bron, Dominique, primary, Aurer, Igor, additional, André, Marc P. E., additional, Bonnet, Christophe, additional, Caballero, Dolores, additional, Falandry, Claire, additional, Kimby, Eva, additional, Soubeyran, Pierre, additional, Zucca, Emanuele, additional, Bosly, Andre, additional, and Coiffier, Bertrand, additional

Published
2017
Full Text
View/download PDF

25. First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa

Author

Thieblemont, Catherine, primary, Tilly, Hervé, additional, Gomez da Silva, Maria, additional, Casasnovas, Rene-Olivier, additional, Fruchart, Christophe, additional, Morschhauser, Franck, additional, Haioun, Corinne, additional, Lazarovici, Julien, additional, Grosicki, Sebastian, additional, Perrot, Aurore, additional, Trotman, Judith, additional, Sebban, Catherine, additional, Caballero, Dolores, additional, Greil, Richard, additional, Van Eygen, Koen, additional, Briere, Josette, additional, Cabecadas, Jose, additional, Salles, Gilles Andre, additional, Gaulard, Philippe, additional, Bosly, Andre, additional, and Coiffier, Bertrand, additional

Published
2016
Full Text
View/download PDF

26. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

Author

Awan, Farrukh T, Hillmen, Peter, Hellmann, Andrzej, Robak, Tadeusz, Hughes, Steven G., Trone, Denise, Shannon, Megan, Flinn, Ian W., Byrd, John C., Riveros, Dardo, Pavlovsky, Santiago, Iastrebner, Claudio M., Carney, Dennis A., Deveridge, Sandra, Durrant, Simon, Hahn, Uwe H., Hertzberg, Mark, Leahy, Michael F., David, Ma, Marlton, Paula, Mulligan, Stephen, Opat, Stephen S., Tiley, Campbell, Wickham, Nicholas W., Cannell, Paul, Gatalano, John, Catalano, John, Cull, Gavin, Luen B., To, Hopfinger, Georg, Jager, Ulrich, Linkesch, Werner, Petzer, Andreas, Schwarzmeier, Josef, Steurer, Michael, Greil, Richard, Bememan, Zwi, Bosly, Andre, Bron, Dominique, Janssens, Ann, Offner, Fritz, Van Den Neste, Eric W., Ka Lung, Wu, Van Hoof, Achiel, Maiolino, Angelo, Pinczowski, Helio, Zanichelli, Maria A., Pereira, Juliana, Larratt, Loree, Spaner, David, Howson Jan, Kang, Chen, Christine I., Cantin, Guy, Fernandez, Louis A., Fraser, Graeme, Mayer, Jiri, Trneny, Marek, Jebavy, Ladislav, Bordessoule, Dominique, Lamy, Thierry, Milpied, Noel, Truchan Graczyk, Malgorzata, Eghbali, Houchingue, Karsenti, Jean Michel, Celigny, Philippe Solal, Mans, Le, Cazin, Bruno, Gyan, Emmanuel, Lepretre, Stephane, Bergmann, Lothar, Tsionos, Konstantinos, Lokeshwar, Nilesh M., Agarwal, Mohan B., Ross, Cecil R., Deshmukh, Chetan D., Narayanan, Geetha, Raina, Vinod, Bondarde, Shailesh A., Shah, Bhavin A., Bairey, Osnat, Tikva, Petach, Shvidel, Lev, Ambrosetti, Achille, Rossi, Policlinico G. B., Angelucci, Emanuele, Carella, Angelo M., Massaia, Massimo, Zinzani, Pier L., Caligaris Cappio, Federico, Foa, Roberto, Gaidano, Gianluca, della Caritá, A. O. Maggiore, Leone, Giuseppe, Santoro, Armando, Griskevicius, Laimonas, Jurgutis, Romualdas, Baker, Bartrum W., Hawkins, Timothy, Corbett, Gillian M., Ganly, Peter, D'Souza, Alvyn B., Deptala, Andrzej, Holowiecki, Jerzy, Kloczko, Janusz, Skotnicki, Aleksander, Zdziarska, Barbara, Kyrcz Krzemien, Slawomira, Dmoszynska, Anna, Moreira, Anna, Pereira, Ana P., Colita, Andrei, Moicean, Andreea D., Vasilica, Mariana, Danaila, Catalin, Gheorghita, Emanuil, Pavlov, Vyacheslav V., Rossiev, Viktor A., Konstantinova, Tatiana, Samoilova, Olga S., Novgorod, Nizhniy, Shelekhova, Tatyana, Zaritsky, Andrey Y., Abdulkadyrov, Kudrat M., Zyuzgin, Ilya S., Pristupa, Alexander S., Loscertales, Javier, Vidal, Joan Besalduch, de Mallorca, Palma, Gonzalez, Marcos, Ortuno, Francisco, Giraldo, Pilar, Nathwani, Amit, Agrawal, Samir G., Rule, Simon, Dearden, Claire E., Bloor, Adrian J., Haynes, Andrew, Singer, Charles, Boclek, Robert G., Bosserman, Linda D., Chan, David, Davidson, Sheldon J., Dichmann, Robert A., Farber, Charles, Hart, Lowell, Hermann, Robert, Eddie, Hu, Janakiraman, Nalini, Jonas, William, Liem, Kiem D., Mcintyre, Rosemary E., O'Brien, Susan, Patel, Giribala, Rado, Thomas, Schilder, Russell, Smith, Scott E., Stock, Wendy, Turturro, Francesco, Venugopal, Parameswaran, Anderson, Thomas C., Berry, William, Boyd, Thomas E., Byrd, John, Cooper, Maureen, Flinn, Ian, Gersh, Robert, Gordon, David, Guzley, Gregory J., Wilks, Sharon T., Klein, Andreas, Krauss, John C., Lister, John, Mandell, Lance, Molina, Arthur, Cooper, Barry, Pendergrass, Kelly B., Reeder, Craig, Savin, Michael A., Spitzer, Gary, Tuscano, Joseph M., Vandeventer, Hendrik, Eradat, Herbert A., Masood, Aisha, Mena, Raul, F. T. Awan, P. Hillmen, A. Hellmann, T. Robak, S. G. Hughe, D. Trone, M. Shannon, I. W. Flinn, J. C. Byrd, L. U. C., and Riveros D, Iastrebner CM, Carney DA, Deveridge S, Durrant S, Hahn UH, Hertzberg M, Leahy MF, Ma D, Marlton P, Mulligan S, Opat SS, Tiley C, Wickham NW, Cannell P, Gatalano J, Cull G, B To L, Catalano J, Wickham NW, Hopfinger G, Jager U, Linkesch W, Petzer A, Schwarzmeier J, Steurer M, Greil R, Bememan Z, Bosly A, Bron D, Janssens A, Offner F, Van Den Neste EW, Wu KL, Van Hoof A, Maiolino A, Pinczowski H, Zanichelli MA, Pereira J, Larratt L, Spaner D, Howson-Jan K, Chen CI, Fernandez LA, Fraser G, Mayer J, Trneny M, Jebavy L, Bordessoule D, Lamy T, Milpied N, Eghbali H, Karsenti JM, Celigny PS, Cazin B, Gyan E, Lepretre S, Bergmann L, Tsionos K, Lokeshwar NM, Agarwal MB, Ross CR, Deshmukh CD, Narayanan G, Raina V, Bondarde SA, Shah BA, Bairey O, Ben-Yehuda D, Shvidel L, Ambrosetti A, Angelucci E, Carella AM, Massaia M, Zinzani PL, Caligaris-Cappio F, Foa R, Gaidano G, Leone G, Santoro A, Griskevicius L, Jurgutis R, Baker BW, Hawkins T, Corbett GM, Ganly P, D'Souza AB, Deptala A, Hellmann A, Holowiecki J, Kloczko J, Skotnicki A, Zdziarska B, Robak T, Dmoszynska A, Moreira I, Pereira AP, Colita A, Moicean AD, Gheorghita E, Vasilica M, Pavlov VV, Rossiev VA, Konstantinova T, Samoilova OS, Novgorod N, Shelekhova T, Zaritsky AY, Abdulkadyrov KM, Zyuzgin IS, Pristupa AS, Loscertales J, Casado LF, Gonzalez M, Ortuno F, Giraldo P, Servet M, Nathwani A, Howson-Jan K, Agrawal SG, Hillmen P, Rule S, Dearden CE, Bloor AJ, Haynes A, Singer C, Boclek RG, Bosserman LD, Chan D, Davidson SJ, Dichmann RA, Farber C, Guzley GJ, Hermann R, Hu E, Janakiraman N, Jonas W, Liem KD, Mcintyre RE, O'Brien S, Patel G, Rado T, Schilder R, Smith SE, Stock W, Turturro F, Venugopal P, Berry W, Boyd TE, Byrd J, Cooper M, Flinn I, Gersh R, Gordon D, Wilks ST, Klein A, Krauss JC, Lister J, Mandell L, Molina A, Pendergrass KB, Reeder C, Savin MA, Spitzer G, Tuscano JM, van Deventer H, Eradat HA, Cooper B, Masood A, Mena R.

Subjects
Oncology, Male, Chronic lymphocytic leukaemia, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Pharmacology, Antibodies, Monoclonal, Murine-Derived, Recurrence, hemic and lymphatic diseases, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, drug therapy, Male, Middle Aged, Recurrence, Vidarabine, Chronic, Aged, 80 and over, Leukemia, Medicine (all), Antibodies, Monoclonal, Hematology, Middle Aged, Adult, Aged, Aged, Lymphocytic, Fludarabine, Tolerability, Small lymphocytic lymphoma, administration /&/ dosage/adverse effects, Female, Humans, Leukemia, Rituximab, Female, Vidarabine, medicine.drug, Adult, Murine-Derived, medicine.medical_specialty, Cyclophosphamide, chemical and pharmacologic phenomena, CD23, Lumiliximab, Aged, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, chronic lymphocytic leukaemia, lumiliximab, small lymphocytic lymphoma, Internal medicine, administration /&/ dosage/adverse effects/analogs /&/ derivatives, 80 and over, Antibodie, Adverse effect, Lymphocytic leukaemia, business.industry, administration /&/ dosage/adverse effects, Antibodie, B-Cell, administration /&/ dosage/adverse effects, Cyclophosphamide, Interim analysis, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocol, business
Abstract

Item does not contain fulltext Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) versus FCR alone in subjects with relapsed CLL; LUCID] was a phase 2/3, randomized (1:1), open-label, multicentre study of lumiliximab in combination with FCR versus FCR alone in patients with relapsed CLL. Six hundred and twenty-seven patients were randomized to either arm. Overall the combination of lumiliximab with FCR was not significantly better than FCR alone (overall response rate 71% vs. 72%, complete response rate 16% vs. 15%, median progression-free survival 24.6 vs. 23.9 months respectively, for FCR with and without lumiliximab). There was a slightly increased incidence of adverse events with lumiliximab but these increases did not appear to lead to differences in eventual outcomes. An interim analysis failed to show sufficient efficacy of the combination of lumiliximab with FCR. The study was therefore stopped early for lack of efficacy. Despite the eventual outcome, the LUCID trial is one of the largest studies that provides valuable insight into the efficacy and tolerability of FCR as a therapeutic option for patients with relapsed CLL.

Published
2014

28. A Randomized Study of Interferon alpha-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma

Author

Bosly, Andre, Grigg, Andrew, Holte, Harald, Gisselbrecht, Christian, Radford, John, Rossi, Andrea, Lopez-Guillermo, Armando, Trneny, Marek, Sebban, Catherine, Hagberg, Hans, da Costa, Fernando Leal, Colombat, Philippe, Bron, Dominique, Coiffier, Bertrand, Bosly, Andre, Grigg, Andrew, Holte, Harald, Gisselbrecht, Christian, Radford, John, Rossi, Andrea, Lopez-Guillermo, Armando, Trneny, Marek, Sebban, Catherine, Hagberg, Hans, da Costa, Fernando Leal, Colombat, Philippe, Bron, Dominique, and Coiffier, Bertrand

Abstract

Background. Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second relapse after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT), interferon (IFN) alpha-2b was given in a prospective randomized international trial. Methods. In this trial, 221 patients with varying histologic diagnoses (8 small lymphocytic, 37 follicular, 9 mantle, 90 diffuse large B-cell, 20 peripheral T-cell, 3 high-grade B-cell non-Hodgkin lymphoma, and 54 Hodgkin lymphoma) were randomly assigned to receive no further treatment (armA: 117 patients) or IFN alpha-2b, 3 MU three times weekly, for 18 months (arm B: 104 patients). Results. In arm B, 21 patients (20%) did not receive IFN alpha-2b because of early progression or absence of hematologic recovery, 29 patients (28%) completed the 18 months of treatment, and 54 patients (52%) interrupted treatment because of progression (23%) or toxicity (29%). Event-free survival and overall survival were not different between the two arms on an intent-to-treat analysis and also if analysis was restricted to patients who were a live and had not experienced disease progression three months after transplantation. The study was not sufficiently powered to evaluate effects in histologic subtypes. Conclusion. In this trial, post-autograft IFN alpha-2b did not improve outcomes in a heterogeneous group of patients with lymphoma.

Published
2013
Full Text
View/download PDF

29. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma : Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

Author

Gisselbrecht, Christian, Schmitz, Norbert, Mounier, Nicolas, Gill, Devinder Singh, Linch, David C., Trneny, Marek, Bosly, Andre, Milpied, Noel J., Radford, John, Ketterer, Nicolas, Shpilberg, Ofer, Duehrsen, Ulrich, Hagberg, Hans, Ma, David D., Viardot, Andreas, Lowenthal, Ray, Briere, Josette, Salles, Gilles, Moskowitz, Craig H., Glass, Bertram, Gisselbrecht, Christian, Schmitz, Norbert, Mounier, Nicolas, Gill, Devinder Singh, Linch, David C., Trneny, Marek, Bosly, Andre, Milpied, Noel J., Radford, John, Ketterer, Nicolas, Shpilberg, Ofer, Duehrsen, Ulrich, Hagberg, Hans, Ma, David D., Viardot, Andreas, Lowenthal, Ray, Briere, Josette, Salles, Gilles, Moskowitz, Craig H., and Glass, Bertram

Abstract

Purpose The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods In total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P=.7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P<.05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P<.001), as was male sex (P=.01). Conclusion In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.

Published
2012
Full Text
View/download PDF

30. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Ribrag, Vincent, Brousse, Nicole, Thieblemont, Catherine, Bouabdallah, Reda, Dohner, Hartrnut, Feugier, Pierre, Forspointner, Roswitha, Haioun, Corinne, Kneba, Michael, Haenel, Mathias, Casasnovas, Olivier, Mertelsmann, Roland H., Hallek, Michael, Bosly, Andre, Nowacki, M., Klapper, Wolfram, Gisselbrecht, Christian, Coiffier, Bertrand, Unterhalt, Michael, Hiddemann, Wolfgang, Dreyling, Martin H., Hermine, Olivier, Hoster, Eva, Walewski, Jan, Ribrag, Vincent, Brousse, Nicole, Thieblemont, Catherine, Bouabdallah, Reda, Dohner, Hartrnut, Feugier, Pierre, Forspointner, Roswitha, Haioun, Corinne, Kneba, Michael, Haenel, Mathias, Casasnovas, Olivier, Mertelsmann, Roland H., Hallek, Michael, Bosly, Andre, Nowacki, M., Klapper, Wolfram, Gisselbrecht, Christian, Coiffier, Bertrand, Unterhalt, Michael, Hiddemann, Wolfgang, and Dreyling, Martin H.

Published
2012

31. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Author

Gisselbrecht, Christian, Glass, Bertram, Mounier, Nicolas, Gill, Devinder Singh, Linch, David C., Trneny, Marek, Bosly, Andre, Ketterer, Nicolas, Shpilberg, Ofer, Hagberg, Hans, Ma, David, Briere, Josette, Moskowitz, Craig H., Schmitz, Norbert, Gisselbrecht, Christian, Glass, Bertram, Mounier, Nicolas, Gill, Devinder Singh, Linch, David C., Trneny, Marek, Bosly, Andre, Ketterer, Nicolas, Shpilberg, Ofer, Hagberg, Hans, Ma, David, Briere, Josette, Moskowitz, Craig H., and Schmitz, Norbert

Abstract

Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown. Patients and Methods Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP). Responding patients received high-dose chemotherapy and ASCT. Results The median age of the 396 patients enrolled (R-ICE, n = 202; R-DHAP, n = 194) was 55 years. Similar response rates were observed after three cycles of R-ICE (63.5%; 95% CI, 56% to 70%) and R-DHAP (62.8%; 95 CI, 55% to 69%). Factors affecting response rates (P < .001) were refractory disease/relapse less than versus more than 12 months after diagnosis (46% v 88%, respectively), International Prognostic Index (IPI) of more than 1 versus 0 to 1 (52% v 71%, respectively), and prior rituximab treatment versus no prior rituximab (51% v 83%, respectively). There was no significant difference between R-ICE and R-DHAP for 3-year event-free survival (EFS) or overall survival. Three-year EFS was affected by prior rituximab treatment versus no rituximab (21% v 47%, respectively), relapse less than versus more than 12 months after diagnosis (20% v 45%, respectively), and IPI of 2 to 3 versus 0 to 1 (18% v 40%, respectively). In the Cox model, these parameters were significant (P < .001). Conclusion In patients who experience relapse more than 12 months after diagnosis, prior rituximab treatment does not affect EFS. Patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.

Published
2010
Full Text
View/download PDF

32. Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study

Author

Delarue, Richard, primary, Tilly, Herve, additional, Salles, Gilles Andre, additional, Thieblemont, Catherine, additional, Bologna, Serge, additional, Ghesquieres, Herve, additional, Hermine, Olivier, additional, Haioun, Corinne, additional, and Bosly, Andre, additional

Published
2013
Full Text
View/download PDF

34. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

Author

Gisselbrecht, Christian, primary, Schmitz, Norbert, additional, Mounier, Nicolas, additional, Singh Gill, Devinder, additional, Linch, David C., additional, Trneny, Marek, additional, Bosly, Andre, additional, Milpied, Noel J., additional, Radford, John, additional, Ketterer, Nicolas, additional, Shpilberg, Ofer, additional, Dührsen, Ulrich, additional, Hagberg, Hans, additional, Ma, David D., additional, Viardot, Andreas, additional, Lowenthal, Ray, additional, Brière, Josette, additional, Salles, Gilles, additional, Moskowitz, Craig H., additional, and Glass, Bertram, additional

Published
2012
Full Text
View/download PDF

35. Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

Author

Dubois, Sydney, Tesson, Bruno, Viailly, Pierre-Julien, Molina, Thierry, Copie-Bergman, Christiane, Mareschal, Sylvain, Bohers, Elodie, Bertrand, Philippe, Ruminy, Philippe, Maingonnat, Catherine, Jais, Jean-Philippe, Peyrouze, Pauline, Figeac, Martin, Desmots, Fabienne, Fest, Thierry, Haioun, Corinne, Lamy, Thierry, Briere, Josette, Petrella, Tony, Canioni, Danielle, Fabiani, Bettina, Coiffier, Bertrand, Delarue, Richard, Peyrade, Frederic, Bosly, André, Andre, Marc, Ketterer, Nicolas, Salles, Gilles A., Tilly, Hervé, Leroy, Karen, and Jardin, Fabrice

Published
2015
Full Text
View/download PDF

37. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, primary, Hoster, Eva, additional, Walewski, Jan, additional, Ribrag, Vincent, additional, Brousse, Nicole, additional, Thieblemont, Catherine, additional, Bouabdallah, Reda, additional, Dohner, Hartmut, additional, Feugier, Pierre, additional, Forspointner, Roswitha, additional, Haioun, Corinne, additional, Kneba, Michael, additional, Hänel, Mathias, additional, Casasnovas, Olivier, additional, Mertelsmann, Roland H., additional, Hallek, Michael, additional, Bosly, Andre, additional, Nowacki, M, additional, Klapper, Wolfram, additional, Gisselbrecht, Christian, additional, Coiffier, Bertrand, additional, Unterhalt, Michael, additional, Hiddemann, Wolfgang, additional, and Dreyling, Martin H., additional

Published
2012
Full Text
View/download PDF

38. Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program

Author

Jardin, Fabrice, primary, Mareschal, Sylvain, additional, Figeac, Martin, additional, Jais, Jean-Philippe, additional, Leroy, Karen, additional, Copie-Bergman, Christiane, additional, Salles, Gilles Andre, additional, Coiffier, Bertrand, additional, Delarue, Richard, additional, Peyrade, Frederic, additional, Bosly, Andre, additional, Ketterer, Nicolas, additional, Haioun, Corinne, additional, Tilly, Herve, additional, and Molina, Thierry Jo, additional

Published
2012
Full Text
View/download PDF

40. FCGR3A and FCGR2A Polymorphisms Do Not Affect Response and Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Study LNH2003

Author

Ghesquieres, Herve, primary, Jardin, Fabrice, additional, Pallardy, Sophie, additional, Verney, Aurélie, additional, Borrel, Anne Laure, additional, Ketterer, Nicolas, additional, Recher, Christian, additional, Delarue, Richard, additional, Bosly, Andre, additional, Coiffier, Bertrand, additional, Casasnovas, Rene-Olivier, additional, Fitoussi, Olivier, additional, Peyrade, Frederic, additional, Ribrag, Vincent, additional, Zelenika, Diana, additional, Tilly, Herve, additional, Haioun, Corinne, additional, and Salles, Gilles Andre, additional

Published
2011
Full Text
View/download PDF

41. Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Program LNH2003,

Author

Ghesquieres, Herve, primary, Jardin, Fabrice, additional, Pallardy, Sophie, additional, Verney, Aurélie, additional, Borrel, Anne Laure, additional, Ketterer, Nicolas, additional, Recher, Christian, additional, Delarue, Richard, additional, Bosly, Andre, additional, Coiffier, Bertrand, additional, Casasnovas, Rene-Olivier, additional, Fitoussi, Olivier, additional, Peyrade, Frederic, additional, Ribrag, Vincent, additional, Zelenika, Diana, additional, Tilly, Herve, additional, Haioun, Corinne, additional, and Salles, Gilles Andre, additional

Published
2011
Full Text
View/download PDF

43. Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05

Author

Ribrag, Vincent, primary, Tilly, Herve, additional, Casasnovas, Olivier, additional, Bosly, Andre, additional, Bouabdallah, Reda, additional, Delarue, Richard, additional, Boue, Francois, additional, Bron, Dominique, additional, Feugier, Pierre, additional, Haioun, Corinne, additional, Offner, Fritz C, additional, and Coiffier, Bertrand, additional

Published
2010
Full Text
View/download PDF

44. Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B

Author

Peyrade, Frederic, primary, Jardin, Fabrice, additional, Gisselbrecht, Christian, additional, Thyss, Antoine, additional, Emile, Jean François, additional, Castaigne, Sylvie, additional, Coiffier, Bertrand, additional, Haioun, Corinne, additional, Bologna, Serge, additional, Fitoussi, Olivier, additional, Lepeu, Gerard, additional, Fruchart, Christophe, additional, Bordessoule, Dominique, additional, Blanc, Michel, additional, Delarue, Richard, additional, Janvier, Maud, additional, Salles, Bruno, additional, Bosly, Andre, additional, and Tilly, Herve, additional

Published
2010
Full Text
View/download PDF

45. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, primary, Hoster, Eva, additional, Walewski, Jan, additional, Ribrag, Vincent, additional, Brousse, Nicole, additional, Thieblemont, Catherine, additional, Bouabdallah, Reda, additional, Stilgenbauer, Stephan, additional, Feugier, Pierre, additional, Forstpointner, Roswitha, additional, Haioun, Corinne, additional, Kneba, Michael, additional, Hänel, Mathias, additional, Casasnovas, Rene-Olivier, additional, Finke, Jürgen, additional, Hallek, Michael, additional, Wandt, Hannes, additional, Bosly, Andre, additional, Klapper, Wolfram, additional, Gisselbrecht, Christian, additional, Coiffier, Bertrand, additional, Hiddemann, Wolfgang, additional, Unterhalt, Michael, additional, and Dreyling, Martin H., additional

Published
2010
Full Text
View/download PDF

46. Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Author

Zucca, Emanuele, primary, Conconi, Annarita, additional, Martinelli, Giovanni, additional, Martelli, Maurizio, additional, Thieblemont, Catherine, additional, Johnson, Peter W, additional, Lopez-Guillermo, Armando, additional, Bouabdallah, Reda, additional, Tucci, Alessandra, additional, Vitolo, Umberto, additional, Coiffier, Bertrand, additional, Devizzi, Liliana, additional, Jardin, Fabrice, additional, Sebban, Catherine, additional, Pinotti, Graziella, additional, Morschhauser, Franck, additional, Pettengell, Ruth, additional, Bosly, Andre, additional, Montserrat, Emili, additional, Bellei, Monica, additional, Pileri, Stefano A., additional, Copie-Bergman, Christiane, additional, Campo, Elias, additional, Jack, Andrew, additional, Mazzucchelli, Luca, additional, and Cavalli, Franco, additional

Published
2010
Full Text
View/download PDF

47. A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

Author

Recher, Christian, primary, Coiffier, Bertrand, additional, Haioun, Corinne, additional, Fermé, Christophe, additional, Molina, Thierry Jo, additional, Casasnovas, Olivier, additional, Gisselbrecht, Christian, additional, Bosly, Andre, additional, Laurent, Guy, additional, Morschhauser, Franck, additional, Ghesquieres, Herve, additional, Jardin, Fabrice, additional, Bologna, Serge, additional, Fruchart, Christophe, additional, Canioni, Danielle, additional, Corront, Bernadette, additional, Gabarre, Jean, additional, Bonnet, Christophe, additional, Janvier, Maud, additional, and Tilly, Herve, additional

Published
2010
Full Text
View/download PDF

48. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Author

Gisselbrecht, Christian, primary, Glass, Bertram, additional, Mounier, Nicolas, additional, Singh Gill, Devinder, additional, Linch, David C., additional, Trneny, Marek, additional, Bosly, Andre, additional, Ketterer, Nicolas, additional, Shpilberg, Ofer, additional, Hagberg, Hans, additional, Ma, David, additional, Brière, Josette, additional, Moskowitz, Craig H., additional, and Schmitz, Norbert, additional

Published
2010
Full Text
View/download PDF

50. Efficacy and Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results of the Interim Analysis of the LNH03-6B GELA Study.

Author

Delarue, Richard, primary, Haioun, Corinne, additional, Broussais-Guillaumot, Florence, additional, Sibon, David, additional, Fournier, Marion, additional, Mounier, Nicolas, additional, Petrella, Tony, additional, Bologna, Serge, additional, Fruchart, Christophe, additional, Ferme, Christophe, additional, Recher, Christian, additional, Picard, Stephanie, additional, Tilly, Herve, additional, and Bosly, Andre, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results